Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2020

Schedule of diluted income (loss) per share

The following table sets forth the potential common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:


	For the Three Months Ended
	March 31,	March 31,
	2020	2019
Unvested restricted stock units/awards	1,201,575	1,065,317
Preferred shares	250,000	250,000
Total potential dilutive effect	1,451,575	1,315,317